Mail: info@sterilize.it  – Linkedin: sterilize.it


  • Member Area
  • Registration
  • About us
  • Processes
  • Applications
  • Bookstore
  • Useful Links
  • Contact us
  • About us
  • Processes
  • Applications
  • Bookstore
  • Useful Links
  • Contact us

Risk Analysis for Aseptic Processing: The Akers-Agalloco Method

Abstract

Aseptic processing is considered by many in this industry to be among the more difficult activities to execute properly. The number of variables that affect the safety of sterile products manufactured aseptically is substantial. In the design and operation of an aseptic production facility, it is essential that risk to the patient be minimized. This article presents a new approach to risk assessment for aseptic processing that emphasizes the contributions of personnel.

Keywords: aseptic processing, risk analysis methods, sterile manufacturing, validation, aseptic filling,
lyophilizatio, decontamination, isolation, microbial contamination.

 

Introduction

In September of 2004, FDA issued a number of guidance documents and regulatory initiatives. Among the guidance documents made available was the long awaited guidance on Sterile Drug Products Produced by Aseptic Processing At essentially the same time, FDA also published “Pharmaceutical CGMPS for the 21st Century – A Risk-Based Approach”. Each of these documents makes reference to the other, but there is no substantive information offered in either to assist the practitioner in establishing a true risk-based approach for the design, and control of contemporary aseptic processing operations.

Numerous, pre-existing risk analysis methods have been adapted for use in the pharmaceutical industry including:

  • Fault Tree Analysis – FTA
  • Failure Mode and Effect Analysis – FMEA
  • Hazard Analysis and Critical Control Point – HACCP
  • Hazard and Operational Studies – HAZOP
  • Failure Mode, Effect and Criticality Analysis – FMECA – adds “criticality” to FMEA

 

These methods have proven to be successful in a variety of applications; however, none was ever specifically intended for application with aseptic processing, which relies of a large number of variables and has the least tolerance for failure of any process in the entire industry. Simply put, failure in aseptic processing is unacceptable and a suitable risk analysis method must incorporate all of the myriad factors impacting product sterility, and thus patient safety. The risk analysis approach utilized must be compatible with the recognition that there is no
acceptable level of risk associated with sterile products, regardless of the method of manufacturing. The goal is, and must always be, perfection in all elements of sterile product manufacture, even where they are made using an aseptic process.iii With this in mind we embarked on an evaluation of prior risk evaluation methods models applied to aseptic processing.

[…]
  • author: Akers James and Agalloco James

The content you requested is only available for registered users. Please, register to download the file.
It's fast and free. Register here.
If you are a registered user enter your e-mail address and password to log in.

• Download
PDF File

0
0
0
0

related articles

  • Key factors in the choice and development of a cleaning strategy
  • Product Stability Issues
  • Flexibility and cost-effectiveness for advanced aseptic production
  • History of isolator and containment technology Part 1: Early containment leading to flexible film isolator
  • A history of isolator and containment technology, Part 6: Development of the validation of isolators

0 Commenti

Leave Reply Annulla risposta

Il tuo indirizzo email non sarà pubblicato. I campi obbligatori sono contrassegnati *

Search
  • Enter your keyword

  • Processes

  • Applications

  • Author

Recent articles
  • A History of Isolator and Containment Technology, Part 5: Development and use of sterilising agents with associated devices
  • A history of isolator and containment technology Part 4: Transfer devices
  • A history of isolator and containment technology Part 3: Non-flexible film isolators including RABS
  • A history of isolator and containment technology Part 2: Flexible film isolators
  • Importance of risk assessment for aseptic transfer in pharmaceutical compounding

Aseptic Processing – Achieving Sterility by Design

Scroll
Contact

Mail: info@sterilize.it
Linkedin: sterilize.it

Member Area
Accesso
Password persa
Process
  • Aseptic processing
  • Cleaning
  • Chemical bio-decontamination
  • Moist-heat sterilization
  • Sterilization
Application
  • Blood bags
  • Environmental Monitoring
  • Food
  • General
  • Hyaluronic Acid
  • Other applications
  • Package Integrity
  • Pharma – Liquids
  • Pharmaceutical compounding
  • Pre-filled syringes (PFSs)
  • Robotics
  • Sealed containers
  • Validation
Subscribe to newsletter

Subscribe to our newsletter to stay informed about our news and info.

Join here

© Copyright 2020 Sterilize.it. All rights reserved. Privacy Policy e Cookie

Fedegari Autoclavi SpA | Albuzzano - SS 235 Km 8, CAP. 27010 (PV) | REA: PV- 130961 | P.IVA IT00303010185 | PEC: amministrazione@pec.fedegari.com | Capitale Sociale Versato 5.000.000,00 € i.v.